Search Results | Blood | American Society of Hematology

1-20 of 54

2 3

Sort by

Sort Order Select

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Blood (2022) 140 (Supplement 1): 292–294.

DOI: https://doi.org/10.1182/blood-2022-159606

Published: 2022

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

DOI: https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2021) 138 (Supplement 1): 1829.

DOI: https://doi.org/10.1182/blood-2021-148423

Published: 2021

Journal Articles

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Blood (2020) 135 (26): 2375–2387.

DOI: https://doi.org/10.1182/blood.2019003382

Published: 2020

Includes: Supplemental data

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

DOI: https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 581.

DOI: https://doi.org/10.1182/blood-2019-127717

Published: 2019

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2019) 134 (Supplement_1): 781.

DOI: https://doi.org/10.1182/blood-2019-125204

Published: 2019

Journal Articles

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 1852.

DOI: https://doi.org/10.1182/blood-2019-128655

Published: 2019

Journal Articles

Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor

Blood (2018) 132 (Supplement 1): 4503.

DOI: https://doi.org/10.1182/blood-2018-99-117431

Published: 2018

Journal Articles

Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma

Blanca Ferrer Lores, MDcal Doctor, Irene Mayorga-Ruiz, Angel Alberich Bayarri, PhD, Daniella Morello-González, MDcal Doctor, Irene Pastor-Galán, MDcal Doctor, Blanca Navarro-Cubells, MD PhD, Alicia Serrano, Ana Isabel Teruel, MDcal Doctor, Rosa Dosdá-Muñoz, MD PhD, Carlos Solano, MD PhD, Luis Marti-Bonmati, MD PhD, Maria Jose Terol, MD PhD

Blood (2018) 132 (Supplement 1): 1703.

DOI: https://doi.org/10.1182/blood-2018-99-119851

Published: 2018

Journal Articles

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Blood (2018) 132 (Supplement 1): 126.

DOI: https://doi.org/10.1182/blood-2018-99-111924

Published: 2018

Journal Articles

Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2018) 132 (Supplement 1): 2142.

DOI: https://doi.org/10.1182/blood-2018-99-112656

Published: 2018

Journal Articles

Development and Validation of a New Tool for the Characterization of Immunoglobulin Gene Rearrangements in Patients with Chronic Lymphocytic Leukemia By Deep Next Generation Sequencing

Azahara Fuentes, Alicia Serrano, Blanca Ferrer, MD, Blanca Navarro, MDPhD, Veronica Lendinez, Laura Olivares, Carmen Ivorra, PhD, Ana Isabel Teruel, MD, Carlos Solano, MD PhD, Maria Jose Terol, MD PhD, Javier F Chaves, PhD

Blood (2017) 130 (Supplement 1): 1714.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1714.1714

Published: 2017

Journal Articles

Clinical, Genomic Profile and Recurrent Somatic Mutations in 205 Chronic Lymphocytic Leukemia Treatment-Naive Patients

Blood (2017) 130 (Supplement 1): 1715.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1715.1715

Published: 2017

Journal Articles

Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2017) 130 (Supplement 1): 402.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.402.402

Published: 2017

Journal Articles

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Blood (2016) 128 (22): 5688.

DOI: https://doi.org/10.1182/blood.V128.22.5688.5688

Published: 2016

Journal Articles

The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival

Blood (2016) 128 (22): 375.

DOI: https://doi.org/10.1182/blood.V128.22.375.375

Published: 2016

Journal Articles

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Blood (2016) 127 (25): 3165–3174.

DOI: https://doi.org/10.1182/blood-2016-03-705319

Published: 2016

Includes: Supplemental data

Journal Articles

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

Blood (2016) 127 (9): 1151–1162.

DOI: https://doi.org/10.1182/blood-2015-10-662320

Published: 2016

Includes: Supplemental data

Journal Articles

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

Blood (2016) 127 (4): 420–425.

DOI: https://doi.org/10.1182/blood-2015-08-666537

Published: 2016

2 3

NARROW

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor

Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Development and Validation of a New Tool for the Characterization of Immunoglobulin Gene Rearrangements in Patients with Chronic Lymphocytic Leukemia By Deep Next Generation Sequencing

Clinical, Genomic Profile and Recurrent Somatic Mutations in 205 Chronic Lymphocytic Leukemia Treatment-Naive Patients

Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only